Bibliographic Details
| Title: |
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. |
| Authors: |
DeMatteo, Ronald P., Ballman, Karla V., Antonescu, Cristina R., Maki, Robert G., Pisters, Peter W. T., Demetri, George D., Blackstein, Martin E., Blanke, Charles D., von Mehren, Margaret, Brennan, Murray F., Patel, Shreyaskumar, McCarter, Martin D., Polikoff, Jonathan A., Tan, Benjamin R., Owzar, Kouros |
| Source: |
Lancet. 3/28/2009, Vol. 373 Issue 9669, p1097-1104. 8p. 3 Graphs. |
| Subjects: |
Imatinib, Gastrointestinal stromal tumors, Immunological adjuvants, Gastrointestinal tumors, Prevention of surgical complications, Protein-tyrosine kinase inhibitors, Gastrointestinal system, Randomized controlled trials, Tumor treatment |
| Abstract: |
The article presents a study seeking to determine if an adjuvant treatment with imatinib mesylate would improve recurrence-free survival following resection of localized gastrointestinal stromal tumor. The methods of the randomized controlled trial involving patients who had complete resection of a primary gastrointestinal stromal tumor at least 3 cm in size is described. Researchers found imatinib significantly improved recurrence-free survival in patients compared to the placebo group. The findings indicate adjuvant imatinib therapy is safe and effective in improving survival after resection of primary gastrointestinal stromal tumor. |
| Database: |
Psychology and Behavioral Sciences Collection |
